EUVIMEDEUVIMED entdecken
Crossref

Immune Checkpoint Inhibitor-Induced Rapid Decline in Hepatitis B Virus Markers Improves the Prognosis of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients

Yujie Ran, Minghui Zhu, Kunyuan Wang, Ying Xia, Yun Zhu, Mengya Zang, Shuai Kang, Qi Li, Xiaoyun Hu, Ying Wang, Fang Liu, Xiaowei Chen und 7 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Yujie Ran und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors, Liver Neoplasms, Hepatitis B virus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited research exists on immune checkpoint inhibitors (ICIs)' antiviral efficacy in hepatitis B virus (HBV)–related hepatocellular carcinoma (HCC). This study aimed to evaluate the impact of ICIs on multiple HBV markers and its correlation with HCC prognosis.

Methods

A retrospective cohort study was performed on 318 HBV-related HCC patients, including 268 who received ICIs (with/without targeted therapy; ICI group) and 50 who received targeted therapy alone (non-ICI group). Levels of quantitative HBsAg (qHBsAg), HBV DNA, HBV RNA, and HBcrAg were monitored. Tumor response was evaluated using RECIST 1.1.

Results

Over a median 8.1-month follow-up, the ICI group showed a significantly greater decrease in all HBV markers. At week 96, the ICI group showed significantly higher cumulative incidences of HBsAg response (loss or ≥0.5 Log10 decline) (41.6% vs 14.9%, P = .006) and HBcrAg response (negativity or ≥1 Log10 decline) (46.3% vs 18.1%, P = .007) than non-ICI group and a significantly faster achievement rate of HBV RNA response (negativity or ≥0.5 Log10 decline) (hazard ratio [HR]: 1.80, 95% CI: 1.08–2.99, P = .021). Notably, the PD-1 inhibitors showed significantly better virological response efficacy than PD-L1 inhibitors (HR = 2.04–5.43). The patients with lower levels of HBV markers at enrollment demonstrated significantly better overall survival. Moreover, patients achieving virological response were associated with significantly better survival outcomes and tumor response, with HR ranging 1.64–8.06.

Conclusions

Immune checkpoint inhibitors demonstrate dual therapeutic effects in HBV-related HCC, significantly reducing multiple HBV markers while concurrently enhancing prognosis in combination with antiviral therapy, emphasizing the importance of sustained virological suppression for optimal HCC outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularImmune Checkpoint InhibitorsLiver NeoplasmsHepatitis B virusHepatitis BHumansFemaleMaleRetrospective StudiesPrognosisMiddle AgedHepatitis B Surface AntigensDNA, ViralAgedAntiviral AgentsRNA, ViralTreatment OutcomeAdult

Stichwörter der Autor:innen

HBV RNAhepatitis B core–related antigenhepatitis B virushepatocellular carcinomaimmune checkpoint inhibitor

Substanzen

Immune Checkpoint InhibitorsHepatitis B Surface AntigensDNA, ViralAntiviral AgentsRNA, Viral

Autor:innen und Institutionen

  • Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Key Laboratory of Infectious Diseases Research in South China, Ministry of Education, Guangzhou, China.
  • Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangzhou, China.
  • Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangzhou, China.

ORCID-Profile: Rong Fan

Förderung

  • Outstanding Youths Development Scheme of Nanfang Hospital
  • Southern Medical University

Zitieren

APA

Ran, Y., Zhu, M., Wang, K., Xia, Y., Zhu, Y., Zang, M., Kang, S., Li, Q., Hu, X., Wang, Y., Liu, F., Chen, X., Zhao, Q., Liu, H., Liu, D., Chen, H., Chen, J., Guo, Y., & Fan, R. (2026). Immune Checkpoint Inhibitor-Induced Rapid Decline in Hepatitis B Virus Markers Improves the Prognosis of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag036

Vancouver

Ran Y, Zhu M, Wang K, Xia Y, Zhu Y, Zang M, et al. Immune Checkpoint Inhibitor-Induced Rapid Decline in Hepatitis B Virus Markers Improves the Prognosis of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag036

BibTeX
@article{Ran2026,
  author = {Ran, Yujie and Zhu, Minghui and Wang, Kunyuan and Xia, Ying and Zhu, Yun and Zang, Mengya and Kang, Shuai and Li, Qi and Hu, Xiaoyun and Wang, Ying and Liu, Fang and Chen, Xiaowei and Zhao, Qian and Liu, Hongyan and Liu, Dingli and Chen, Huaiyu and Chen, Jinzhang and Guo, Yabing and Fan, Rong},
  title = {Immune Checkpoint Inhibitor-Induced Rapid Decline in Hepatitis B Virus Markers Improves the Prognosis of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag036}
}
Kostenlos starten →